Merus N.V., a biotechnology firm specializing in oncology, has announced a proposed underwritten public offering of its common shares. All shares in this offering will be provided by Merus, with an additional option for underwriters to purchase up to 15% more shares. The company plans to use the proceeds to further the clinical development of its product candidates and for general corporate purposes. The offering, managed by Jefferies, BofA Securities, Leerink Partners, and others, is contingent on market and closing conditions. A preliminary prospectus supplement will be available on the SEC's website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。